Objective: To evaluate the prognostic value of presepsin and procalcitonin in patient with urosepsis. Material & Method: This is an observational prospective study. Patients who fulfilled the criteria for urosepsis at Soetomo Hospital Surabaya were enrolled. Presepsin and procalcitonin were measured at first admission. All patients were managed according to standard urosepsis therapy. At the 28th day of treatment, patients were evaluated and classified into survivor and non-survivor. The statistical analysis were tested with logistic regression test using software SPSS 23. Results: 30 urosepsis patients were included in this study with average age was 48.3 years (range 21-77 years). There were 23 survivor and 7 non-survivor. Mean presepsin values were higher in non-survivor than in survivor but the difference was not significant (4405 ± 4664 vs 4042 ± 2643, p=0.259). Mean procalcitonin value was significantly higher in non-survivor than in survivor (7.68 ± 6.81 vs 3.27 ± 2.74, p=0.013). Using the cut off value ≥2.24 ng/ml, procalcitonin can predict mortality in 28 days with sensitivity 71.4% and specificity 47.8%. Conclusion: Presepsin can not be used to determine the prognosis of urosepsis patients. Procalcitonin showed a significant correlation with outcome of urosepsis patients so it can be use to determine the prognosis of urosepsis.
Urosepsis, prognostic, mortality, presepsin, procalcitonin
Naber K, Wagenlehner FME, Pilatz A, Weidner W, Naber KG. Urosepsis: Overview of the diagnostic and urosepsis. Overview of the Diagnostic and Treatment Challenges Associated with Urosepsis. Microbiol Spectr; 2015.
Lichtenstern C, Uhle F, Wagenlehner FME, Lichtenstern C, Rolfes C, Mayer K, et al. Diagnosis and management for urosepsis. Int J Urol. 2013 May; 20: 963–70.
Wagenlehner FME, Pilatz A, Weidner W. International Journal of Antimicrobial Agents Urosepsis—from the view of the urologist. Int J Antimicrob Agents. 2011; 38: 51–7.
Singer M, Deutschman CS, Seymour CW, Shankar-hari M. The 3rd International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA. 2017; 315(8): 801–10.
Moss M. The Epidemiology of Sepsis in the United States from 1979 through 2000. N Engl J Med; 2003. p. 1546–54.
Dellinger R, Levy M, Rhodes A. Surviving Sepsis Campaign. Crit Care Med; 2012.
Bonkat G, Pickard R, Bartoletti R, Associate TCG, Associate BKG. Guidelines on Urological Infections. In: European Association of Urology; 2017. p. 22–6.
Fleischmann C, Scherag A, Adhikari N. Assessment of Global Incidence and Mortality of Hospital-treated Sepsis. Am J Respir Crit Care Med. 2015; 193: 259–72.
Henriquez-camacho C, Losa J. Biomarkers for Sepsis. Hindawi; 2014.
Hausfater P. Biomarkers and infection in the emergency unit. Elsevier [Internet]. 2014; 44(4): 139–45.
El-shafie ME, Taema KM, El-hallag MM. The Egyptian Journal of Critical Care Medicine Role of presepsin compared to C-reactive protein in sepsis diagnosis and prognostication. Egypt J Crit Care Med.
Endo S, Suzuki Y, Takahashi G, Nishida T, Irie Y, Miura M. Presepsin as a powerful monitoring tool for the prognosis and treatment of sepsis : A multicenter prospective study. J Infect Chemother.
Pietropaoli A, Glance L, Oakes D, Fisher S. Gender Differences in Mortality in Patients with Severe Sepsis and Septic Shock. Gend Med. 2012; 7(5): 422–37.
Dwimantoro P, Santoso A, Hardjowijoto S. Perbedaan Kadar Laktat Plasma dibandingkan dengan C-Reactive Protein (CRP) sebagai Indikator dalam Menentukan Prognosis Pasien dengan Urosepsis. Dep Urol FK UNAIR; 2014.
Suberviola B, Castelanos-Ortega A, González-Castro A. Prognostic value of procalcitonin, C-reactive protein and leukocytes in septic shock. Med Intensiva. 2012; 36(3).
Klouche K, Cristol JP, Devin J, Gilles V, Kuster N, Larcher R, et al. Diagnostic and prognostic value of soluble CD14 subtype (Presepsin) for sepsis and community - acquired pneumonia in ICU patients. Ann Intensive Care.
Ranieri VM, Reinhart K, Gerlach H, Moreno R. Sepsis in European intensive care units: Results of the SOAP study. Crit Care Med. 2006; 34(2).
Mcpherson D, Griffiths C, Williams M, Baker A, Klodawski E, Jacobson B, et al. Sepsis-associated mortality in England: An analysis of multiple cause of death data from 2001 to 2010. BMJ Open; 2013. p. 1–8.
Masson S, Caironi P, Spanuth E, Thomae R, Panigada M, Sangiorgi G, et al. Presepsin (soluble CD14 subtype) and procalcitonin levels for mortality prediction in sepsis: Data from the Albumin Italian Outcome Sepsis trial. Crit Care Med; 2014. p. 18.
Spanuth E, Ebelt H, Ivandic B, Werdan K. Diagnostic and prognostic value of presepsin (soluble CD14 subtype) in emergency patients with early sepsis using the new assay PATHFAST Presepsin. In: Advances in Clinical Chemistry and Laboratory Medicine; 2012. p. 128–33.
Ulla M, Pizzolato E, Lucchiari M, Loiacono M, Soardo F, Forno D, et al. Diagnostic and prognostic value of presepsin in the management of sepsis in the emergency department: A multicenter prospective study. Crit Care; 2013. p. 1–8.
Chenevier-gobeaux C, Trabattoni E, Roelens M, Borderie D, Claessens Y. Presepsin (sCD14-ST) in emergency department: The need for adapted threshold values? Clin Chim Acta.
Jain S, Sinha S, Sharma SK, Samantaray JC, Aggrawal P, Vikram NK, et al. Procalcitonin as a prognostic marker for sepsis: A prospective observational study. BMC. 2014; (July 2011): 1–7.
Yin Q, Liu B, Chen Y, Zhao Y, Li C. The role of soluble thrombomodulin in the risk stratification and prognosis evaluation of septic patients in the emergency department. Thromb Res. 2013; 132(4): 471–6.
Li Z, Wang H, Liu J, Chen B, Li G. Serum Soluble Triggering Receptor Expressed on Myeloid Cells-1 and Procalcitonin Can Reflect Sepsis Severity and Predict Prognosis: A Prospective Cohort Study. Hindawi; 2014.
Kenzaka T, Okayama M, Kuroki S, Fukui M, Yahata S, Hayashi H, et al. Use of a semiquantitative procalcitonin kit for evaluating severity and predicting mortality in patients with sepsis. Int J Gen Med. 2012; 5: 483–8.
Liu D, Su L, Han G, Yan P, Xie L. Prognostic Value of Procalcitonin in Adult Patients with Sepsis: A Systematic Review and Meta-Analysis. PLoS One; 2015. p. 1–15.
Kru S, Ewig S, Marre R, Papassotiriou J, Richter K, Suttorp N. Procalcitonin predicts patients at low risk of death from community-acquired pneumonia across all CRB-65 classes. Eur Respir J. 2008; 31(2): 349–55.
Kellum JA, Yealy DM, Martino M, Angus DC. Risk Prediction With Procalcitonin and Clinical Rules in Community-Acquired Pneumonia. Ann Emerg Med; 2008. p. 65.
Hillas G, Vassilakopoulos T, Plantza P, Rasidakis A, Bakakos P. C-reactive protein and procalcitonin as predictors of survival and septic shock in ventilator-associated pneumonia. Eur Respir J. 2010; 35(4): 805–11.
Schmidt J, Hiittner H, Erlangen D, Htittner MMJSH, Tschaikowsky K, Jena D. The natural elimination rate of procalcitonin in patients with normal and impaired renal function. Intensive; 2000. p. 212–6.